GIP
BPMC

Granite Investment Partners’s Blueprint Medicines BPMC Stock Holding History

Granite Investment Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,914
Closed -$1.85M – 261
2025
Q1 		$1.85M Sell
20,914
-2,341
-10% -$228K 0.09% 185
2024
Q4 		$2.03M Buy
+23,255
New +$2.13M 0.09% 189

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Granite Investment Partners's BPMC Position: Q2 2025 in Review

Granite Investment Partners sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 20,914 shares — an estimated $1.85M sold.

Granite Investment Partners first reported a position in BPMC in Q4 2024 and held it in 2 quarters. The position peaked at $2.03M in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Granite Investment Partners reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Granite Investment Partners sold 20,914 Blueprint Medicines shares in Q2 2025, an estimated $1.85M.
  • Granite Investment Partners first reported a position in Blueprint Medicines in Q4 2024 and held it in 2 quarters.
  • Granite Investment Partners's Blueprint Medicines position peaked at $2.03M in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Granite Investment Partners's 13F filing for Q2 2025, filed 13 Aug 2025.